European Journal of Clinical Pharmacology

, Volume 74, Issue 4, pp 433–442 | Cite as

Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis

  • Ping Wang
  • Xiao-Qian Lin
  • Wen-Ke Cai
  • Gui-Li Xu
  • Meng-Di Zhou
  • Mei Yang
  • Gong-Hao HeEmail author



Valproic acid (VPA) is one of the most widely used antiepileptic drugs. Recently, increasing evidence suggested that polymorphisms in UGT2B7 gene were associated with VPA pharmacokinetics, but results remained controversial. Therefore, a meta-analysis was performed to derive a more precise evaluation between C802T, C161T, and G211T polymorphisms and plasma concentration of VPA.


The PubMed, EMBASE, and the Cochrane library databases were searched for eligible studies. Articles meeting the inclusion criteria were comprehensively reviewed, and the available data were accumulated. The mean difference (MD) and 95% confidence interval (CI) were applied to assess the strength of the relationship.


A total of 12 studies involving 1996 related East Asia epilepsy patients were assessed. We found that the UGT2B7 G211T polymorphism was associated with adjusted plasma VPA concentration (GG versus TT: P = 0.01, I 2 = 97%; GG versus GT: P < 0.00001, I 2 = 0%). Additionally, we also observed a significantly association between the C161T polymorphism and adjusted plasma VPA concentration (CC versus CT: P = 0.01, I 2 = 77%). Nevertheless, the pooled analysis showed that the C802T polymorphism had no significant effect on adjusted serum concentration of VPA.


The results of this meta-analysis demonstrated that UGT2B7 G211T and C161T polymorphisms were able to affect the pharmacokinetics in epilepsy patients treated with VPA, which provide further evidence for genetic effects of UGT2B7 gene on pharmacokinetics and pharmacodynamics of VPA. Epilepsy patients with these genotypes may be necessary to increase (or decrease) VPA dose to ensure its therapeutic effect.


Valproic acid Plasma concentration Pharmacokinetics Single-nucleotide polymorphism UGT2B7 Meta-analysis 


Funding information

This work was supported by grants from the National Science Foundation of China (No. 81460560) and the Applied Basic Research Program of Yunnan Province (No. 2017FB134).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2017_2395_MOESM1_ESM.doc (50 kb)
ESM 1 (DOC 50 kb)


  1. 1.
    Göttlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83:S91–S92PubMedGoogle Scholar
  2. 2.
    Jawień W, Wilimowska J, Kłys M, Piekoszewski W (2017) Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning. Pharmacol Rep 69(2):340–349. CrossRefPubMedGoogle Scholar
  3. 3.
    Granneman GR, Wang SI, Machinist JM, Kesterson JW (1984) Aspects of the metabolism of valproic acid. Xenobiotica 14(5):375–387. CrossRefPubMedGoogle Scholar
  4. 4.
    Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY (2017) Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy Res 132:64–69. CrossRefPubMedGoogle Scholar
  5. 5.
    Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27(5):536–542. CrossRefPubMedGoogle Scholar
  6. 6.
    Ebner T, Burchell B (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21(1):50–55PubMedGoogle Scholar
  7. 7.
    Du Z, Jiao Y, Shi L (2016) Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children. Med Sci Monit 22:4107–4113. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, Liou HH (2011) Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 12(8):1107–1117. CrossRefPubMedGoogle Scholar
  9. 9.
    Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 26(1):73–77PubMedGoogle Scholar
  10. 10.
    Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A (2006) Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39(3):303–308. CrossRefPubMedGoogle Scholar
  11. 11.
    Bhasker CR, McKinnon W, Stone A, Lo ACT, Kubota T, Ishizaki T, Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8):679–685. CrossRefPubMedGoogle Scholar
  12. 12.
    Sun Y, Zhuo W, Lin H et al (2015) The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res 114:78–80. CrossRefPubMedGoogle Scholar
  13. 13.
    Wang Q, Zhao L, Liang M, Dong Y, Yun W, Qiu F, Meng H, Guo Y (2016) Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine. Ther Drug Monit 38(3):343–349. CrossRefPubMedGoogle Scholar
  14. 14.
    Chu X, Zhang L, Wang G, Zhang S, Zhou J, Hao H (2012) Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 68(10):1395–1401. CrossRefPubMedGoogle Scholar
  15. 15.
    Sun Y, Yu J, Yuan Q, Wu X, Hu J et al (2017) Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury. Scand J Trauma Resusc Emerg Med 25(1):85. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wen Z, Fan S, Du C, Yin T, Zhou B et al (2016) Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients. Pharmacogenomics 17(11):1219–1225. CrossRefPubMedGoogle Scholar
  17. 17.
    Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. CrossRefPubMedGoogle Scholar
  18. 18.
    Reny J, Combescure C, Daali Y et al (2012) Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 10(7):1242–1251. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chatzistefanidis D, Lazaros L, Giaka K, Nakou I, Tzoufi M, Georgiou I, Kyritsis A, Markoula S (2016) UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels. Pharmacogenomics 17(8):827–835. CrossRefPubMedGoogle Scholar
  20. 20.
    Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K (2014) Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 36(3):406–409. CrossRefPubMedGoogle Scholar
  21. 21.
    Ma H, Zhang T, Gong Z, Zhou B, Zou M, Xiao S, Zhu W (2013) Effect of UGT2B7 genetic variants on serum valproic acid concentration. Zhong Nan Da Xue Xue Bao Yi Xue Ban 38(8):766–772. PubMedGoogle Scholar
  22. 22.
    Zhang H, Zhang W, Li Y et al (2017) Correlations between UGT2B7∗2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. Brain Dev S0387-7604(17):30241–30243Google Scholar
  23. 23.
    Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, Wu S (2011) Allergy and risk of glioma: a meta-analysis. Eur J Neurol 18(3):387–395. CrossRefPubMedGoogle Scholar
  24. 24.
    Chadwick DW (1985) Concentration-effect relationships of valproic acid. Clin Pharmacokinet 10(2):155–163. CrossRefPubMedGoogle Scholar
  25. 25.
    Huo T, Chen X, Lu X, Qu L, Liu Y, Cai S (2014) An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach. J Chromatogr B Analyt Technol Biomed Life Sci 969:109–116. CrossRefPubMedGoogle Scholar
  26. 26.
    Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 94(2):261–271. CrossRefPubMedGoogle Scholar
  27. 27.
    Holthe M, Rakvåg TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, Skorpen F (2003) Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3(1):17–26. CrossRefPubMedGoogle Scholar
  28. 28.
    Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 424(2):219–225. CrossRefPubMedGoogle Scholar
  29. 29.
    Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen PX, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18(8):683–697. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Chung JY, Cho JY, Yu KS et al (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83(4):595–600. CrossRefPubMedGoogle Scholar
  31. 31.
    Liu L, Zhao L, Wang Q, Qiu F, Wu X, Ma Y (2015) Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7-161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol 71(11):1341–1347. CrossRefPubMedGoogle Scholar
  32. 32.
    Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI (1993) cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194(1):496–503. CrossRefPubMedGoogle Scholar
  33. 33.
    Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ (2003) A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73(6):566–574. CrossRefPubMedGoogle Scholar
  34. 34.
    Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E (2006) The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res 70(2–3):153–160. CrossRefPubMedGoogle Scholar
  35. 35.
    Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM (1984) Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 17(6):665–669. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Butler JM, Begg EJ (2008) Free drug metabolic clearance in elderly people. Clin Pharmacokinet 47(5):297–321. CrossRefPubMedGoogle Scholar
  37. 37.
    Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66(1):125–133. CrossRefPubMedGoogle Scholar
  38. 38.
    Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106(1):97–132. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Ping Wang
    • 1
    • 2
  • Xiao-Qian Lin
    • 1
    • 3
  • Wen-Ke Cai
    • 4
  • Gui-Li Xu
    • 1
  • Meng-Di Zhou
    • 1
    • 2
  • Mei Yang
    • 1
    • 3
  • Gong-Hao He
    • 1
    Email author
  1. 1.Department of PharmacyKunming General Hospital of PLAKunmingChina
  2. 2.Kunming Medical UniversityKunmingChina
  3. 3.School of PharmacyDali UniversityDaliChina
  4. 4.Department of Cardio-Thoracic SurgeryKunming General Hospital of PLAKunmingChina

Personalised recommendations